Dr. Dyer's Curriculum Vitae

  1. Home
  2. Our Specialists
  3. David S. Dyer, M.D.
  4. Dr. Dyer's Curriculum Vitae

David S. Dyer, M.D., F.A.C.S.

Work History

May 1, 1999 -PRESENT:

  • Retina Associates, LLC
    8600 Quivira Road
    Lenexa, KS 66215
  • Retina Associates, LLC
    6201 College Boulevard
    Suite 200
    Overland Park, KS 66211
  • Retina Associates. LLC
    4100 North Mulberry Drive
    Suite 100
    Kansas City, MO 64116
  • Retina Associates, LLC
    6001 SW 6th Avenue
    Suite 300
    Topeka, KS 66615
  • Retina Associates, LLC
    3400 W 10th Street
    Sedalia, MO 65301
  • Retina Associates, LLC
    100 NE Missouri Road
    Suite 203
    Lee's Summit, MO 64086

January 1, 1997- April 30, 1999:

  • Mid-America Retina Consultants, P. A.
    4321 Washington Street
    Suite 5000
    Kansas City, MO 64111

July 7, 1994 - March 15, 1997:

  • Illinois Retina Associates, S.C.
    71 W. 156th Street
    Suite 400
    Harvey, IL 60426

Education

  • Preparatory: Annandale High School, Annandale, Virginia
  • Undergraduate: George Mason University, Fairfax Virginia
  • Medical: University of Kansas School of Medicine, Kansas City, Kansas
  • Internship: Medicine - University of Kansas Medical Center, Kansas City, Kansas, Department of Internal Medicine (April 1, 1989 - June 30, 1990)
  • Residency: Ophthalmology - Medical University of South Carolina, Storm Eye Institute, Charleston, South Carolina (July 1, 1990 - June 30, 1993)
  • Fellowship: Medical Retina - The Wilmer Ophthalmological Institute, The Johns Hopkins University, Baltimore, Maryland (July 7, 1993 - June 30,1994) Fellowship Director: Andrew P. Schachat, M.D.
  • Fellowship: Surgical Retina - Rush-Presbyterian Hospital/Ingalls Memorial Hospital, Illinois Retina Associates, Harvey, Illinois (July 7, 1994 - June 30, 1995) Fellowship Director: Kirk H. Packo, M.D.

Degrees Earned

  • B.S. - January 1984
  • M.D. - May 1989

Licensure

  • Diplomat American Board of Ophthalmology
  • Kansas State License
  • Missouri State License
  • Utah State License

Memberships

  • American Academy of Ophthalmology
  • Kansas Medical Society
  • Kansas State Ophthalmological Society
  • Kansas City Society of Ophthalmology and Otolaryngology
  • Kansas City Society of Ophthalmology and Otolaryngology Journal Club
  • Kansas City Medical Society
  • Missouri State Medical Association
  • Kansas Society of Eye Physicians & Surgeons
  • Missouri Society of Eye Physicians & Surgeons
  • F.R.A.M.E.
  • Chicago Medical Society
  • Wilmer Residents Associate
  • ARVO
  • ASRS

Academic Appointment

  • Assistant Professor, Rush Medical College, Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Illinois (July 7, 1995 - December 31, 1996)

Publications

  • A Kiri, DS Dyer, NM Bressler, SB Bressler, AP Schachat: “Detection of Diabetic Macular Edema: Nidek 3Dx Stereophotography Compared with Fundus Biomicroscopy.” American Journal of Ophthalmology November 1996
  • PJ Gurecki, KR Holden, EE Sahn, DS Dyer, JR Cure: "Developmental Neural Abnormalities and Seizures in Epidermal Nevus Syndrome.” Developmental Medicine and Child Neurology 1996;38:716-723
  • DS Dyer, AM Brant, AP Schachat, SB Bressler, NM Bressler: "Angiographic Features and Outcome of Questionable Recurrent Choroidal Neovascularization." American Journal of Ophthalmology 1995;120:497-505
  • DS Dyer: “Scleral Patch Graft for Closure of Sclerotomies.” Vitreoretinal Surgery and Technology 1995;7(3):1-4
  • DS Dyer, NM Bressler: “Laser Wavelength-It’s Role in the Treatment of Vitreoretinal Diseases.” Current Opinion in Ophthalmology 1994;5:III:35-43
  • DS Dyer, KW Small, ME Wilson, GS Pai: “Alstrom Syndrome: "A Case Misdiagnosed as Bardet-Biedl Syndrome.” Journal of Pediatric Ophthalmology and Strabismus 1994;31:272-274

Presentations

  • DS Dyer: “Look Deep Into My Eyes.” Greater Kansas City ASORN, Kansas City, Missouri (March 27, 2010)
  • DS Dyer: “Integrated Pressure Infusion and IOP Control.” Constellation Vision System (November 6, 2008)
  • DS Dyer, GM Fox, BA Cooper: “Outcomes and Complications of 25-gauge Vitrectomies.” Masters of the ASRS, Nassau, Bahamas (March 13-16, 2005)
  • DS Dyer: “Babes in Arms - Retinopathy of Prematurity.” Greater Kansas City ASORN, Kansas City, Missouri (February 28, 2004)
  • DS Dyer: “Diabetic Retinopathy and Cataract Surgery.” The Art of Diabetic Care Conference, Kansas City, Missouri (September 20, 1997)
  • A Kiri, SR O’Connell, DS Dyer, NM Bressler, SB Bressler, AP Schachat, D Finkelstein: “Comparison of Stereo Photography by Nidek 3Dx Camera with Zeiss Camera in Detecting Diabetic Macular Edema.” ARVO Annual Meeting, Fort Lauderdale, Florida (May 11-16, 1997)
  • DS Dyer, A Kiri, SR O’Connell, NM Bressler, SB Bressler, AP Schachat: “Intra- and Inter-Observer Agreement in Detecting Diabetic Macular Edema by Grading Nidex 3DX Stereo Photographs.” ARVO Annual Meeting, Fort Lauderdale, Florida (May 11-16, 1997)
  • SR O’Connell, A Kiri, DS Dyer, CJ Hiner, NM Bressler, SB Bressler, AP Schachat: “The Influence of Training Ophthalmologist to Grade Fundus Stereo Photographs for Detecting Diabetic Macular Edema.” ARVO Annual Meeting, Fort Lauderdale, Florida (May 11-16, 1997)
  • DS Dyer: “Diabetes I - Medical Consideration, ETDRS, DCCT and Eurodiab IDDM Trial Results, Nonproliferative Diabetic Retinopathy.” The 6th Annual Rush Medical College Ophthalmology Clinical Review Course, Chicago, Illinois (April 13, 1997)
  • DS Dyer: “Current Concepts and Indications for Vitreo-Retinal Surgery.” Copley-Mercy Consortium, Aurora, Illinois (November 5, 1996)
  • DH Orth, DS Dyer: “Foveal Sparing Photocoagulation for Exudative Age Related Macular Degeneration.” The First Jerusalem International Congress On Retinal and Vitreous Diseases, Jerusalem, Israel (June 30 - July 4, 1996)
  • DS Dyer: “Disorders of the Posterior Pole.” Diagnostic Pharmaceutical Agent Training and Certification Course, The National Eye Research Foundation, Oak Lawn, Illinois (March 23-24, 1996)
  • DS Dyer: “Subretinal Surgery: Advances in Indications and Techniques.”The 5th Annual Rush Medical College Ophthalmology Clinical Review Course, Chicago, Illinois (March 24, 1996)
  • DS Dyer: “Anatomy and Pathophysiology of Age-Related Macular Degeneration.” The 5th Annual Rush Medical College Ophthalmology Clinical Review Course, Chicago, Illinois (March 22, 1996)
  • DS Dyer: “Diabetic Retinopathy.” The Lions of Illinois Foundation Executive Meeting, Peoria, Illinois (February 16, 1996)
  • DS Dyer: “Techniques of Silicone Oil Removal.” Silicone Oil Surgery: A Multi-Centered Course, Chicago, Illinois (October 14, 1995)
  • DS Dyer, KH Packo, R Shetty: “YAG Posterior Hyaloidotomy for Subhyaloid Hemorrhage.” The Retina Society, Twenty-Sixth Scientific Session, London, England (September 6-10, 1995)
  • DS Dyer, LM Jampol, KH Packo: “Evaluation of Computerized Overlay Techniques in Digital Angiography.” ARVO Annual Meeting, Fort Lauderdale, Florida (May 14-19, 1995)
  • A Kiri, DS Dyer, NM Bressler, SB Bressler, AP Schachat: “Comparison of Nidek 3Dx Camera with Fundus Biomicroscopy in the Detection of Diabetic Edema.” ARVO Annual Meeting, Fort Lauderdale, Florida (May 14-19, 1995)
  • A Kiri, DS Dyer, NM Bressler, SB Bressler, AP Schachat: “Comparison of Nidek 3Dx Camera with Fundus Biomicroscopy in the Detection of Diabetic Edema.” The 54th Clinical Meeting of the Wilmer Residents Association (April 27-29, 1995)
  • DS Dyer: “Diabetic Retinopathy: Review of Diabetes Mellitus, DCCT Trial and the ETDRS Trial.” The 4th Annual Rush Medical College Ophthalmology Clinical Review Course, Chicago, Illinois (March 12, 1995)
  • DS Dyer, AM Brant, AP Schachat, SB Bressler, NM Bressler: “Patterns of Questionable Recurrent Choroidal Neovascularization.” ARVO Annual Meeting, Sarasota, Florida (May 1-5, 1994)
  • AM Brant, DS Dyer, AP Schachat, Bressler SB, Bressler NM: “Subtle Clinical Signs of Recurrent Choroidal Neovascularization.” ARVO Annual Meeting, Sarasota, Florida (May 1-5, 1994)
  • DS Dyer, AM Brant, AP Schachat, SB Bressler, NM Bressler: “Patterns of Questionable Recurrent Choroidal Neovascularization.” 53rd Clinical Meeting of the Wilmer Residents Association (April 21-23, 1994)
  • AM Brant, DS Dyer, AP Schachat, SB Bressler, NM Bressler: “Subtle Clinical Signs of Recurrent Choroidal Neovascularization.” 53rd Clinical Meeting of the Wilmer Residents Association (April 21-23, 1994)
  • DS Dyer, YY Palesch, LP King: “Ocular Hypertension Following Pars Plana Vitrectomy.” Poster at the 1993 American Academy of Ophthalmology Annual Meeting, Chicago, Illinois (November 14-18, 1993)
  • DS Dyer, LP King: “Ocular Hypertension Following Pars Plana Vitrectomy.” Pediatric and Strabismus Update, Kiawah Island, South Carolina (June 1-3, 1993)
  • DS Dyer, LP King: “Risk Factors and Treatment of Postoperative Intraocular Pressure Spike Following Vitrectomy.” ARVO Annual Meeting, Sarasota, Florida (May 2-7, 1993)
  • DS Dyer: “Infection Control in the Office.” 1992 Corneal and External Disease Update, Charleston, South Carolina (May 22-24, 1992)
  • DS Dyer: “Post-op Pressure Rise in Intravitreal Gas Injection.” 1992 Corneal and External Disease Update, Charleston, South Carolina (May 22-24, 1992)
  • DS Dyer, KW Small, ME Wilson, GS Pai: “Alstrom Syndrome: A Case Misdiagnosed as Bardet-Biedl Syndrome.” The 14th Annual Ophthalmic Genetics Study Club, Anaheim, California (October 12, 1991)
  • DS Dyer: “Indications and Usage of Low Dose Fluorescein Angiograms.” Glaucoma Diagnostic and Therapeutic Update, Kiawah Island, South Carolina (April 12-14, 1991)

Articles In Preparation

  • AM Brant, DS Dyer, AP Schachat, SB Bressler, NM Bressler: “Subtle Signs of Questionable Recurrent Choroidal Neovascularization.” (Submitted to Retina)
  • DS Dyer, KH Packo: “Retinotomies and Retinectomies.” (To be published in Ophthalmic Practice)

Clinical Research

  • Alcon: C-01-99, Sub-Investigator, Posterior Juxtascleral Injection of Anecortave Acetate versus Sham for Inhibition of CNV in Non-Exudative AMD, 08/2003 – 08/2005.
  • Alcon: C-05-62, Principal Investigator, Clinical Evaluation of the Safety and Efficacy of Preservative-Free Triamcinolone Acetonide Sterile Suspension for Visualization During Vitreoretinal Surgery, 08/2007 - 09/2007.
  • Alcon: C-02-60, Sub-Investigator, Anecortave Acetate Risk Reduction Trial for Patients with Non-Neovascular AMD, 03/2004-08/2008.
  • Alcon: C-04-59, Sub-Investigator, Interval Dose Evaluation of Anecortave Acetate for those with Neovascular AMD, 01/2005 – 02/2008.
  • Alcon: C-12-006, Sub-Investigator, Eylea vs. ESBA1008 for the Treatment of Exudative Age-Related Macular Degeneration, 03/2013 - 04/2013.
  • Alcon: RTH258-C001, Sub-Investigator, Intravitreal RTH258 vs. Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration, 03/2015 - present.
  • Allergan: 206207-008, Sub-Investigator, Posurdex Retinal Vein Occlusion, 01/2005 – 02/2009.
  • Allergan: 206207-010, Sub-Investigator, Posurdex Diabetic Macular Edema, 03/2005 – 03/2013.
  • Allergan: 208397-001, Sub-Investigator, AGN-208397 Retinal Vein Occlusion, 11/2010 -04/2013.
  • DRCR: Intravitreal Triamcinolone study B, Principal Investigator, Focal Laser Treatment versus Intravitreal Injection Triamcinolone for Treatment of Diabetic Macular Edema, 06/2005 – 10/2006.
  • DRCR: Protocol T, Sub-Investigator, Aflibercept, Bevacizumab, and Ranibizumab for the Treatment of Diabetic Macular Edema, 12/2012 - 08/2015
  • DRCR: Protocol V, Sub-Investigator, Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity, 11/2013 - present.
  • DRCR: Protocol W, Sub-Investigator, Intravitreal Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk, 02/2016 - present.
  • DRCR: Protocol AA, Sub-Investigator, Peripheral Diabetic Retinopathy Lesions on Ultrawide-Field Images and Risk of Diabetic Retinopathy Worsening Over Time, 07/2014 - present.
  • Eyetech/OSI: EOP1023, Principal Investigator, Intravitreal Injection of Pegaptanib Sodium for Neovascular AMD, 05/2006 – 07/2008.
  • Eyetech IST: Principal Investigator, Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease (PRESERVE), Sub-Investigator, Intravitreal Injections of Pegaptanib Every 4 weeks Compared to every 6 weeks for the Treatment of Diabetic Macular Edema, 05/2009 - 10/2011.
  • Eyetech: EOP1024, Investigator, Intravitreal Injection of Pegaptanib Sodium administered every 6 weeks for 48 weeks for Subfoveal Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, or Retinal Vein Occlusion to Determine the Adverse Effects on the Corneal Endothelium, 04/2010 – 10/2013.
  • Genaera: 301, Principle Investigator, Squalamine Lactate IV Infusion for Treatment of Neovascular AMD, 09/2005 – 09/2008.
    -Genentech: FVF4165g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Branch Retinal Vein Occlusion, 02/2008 – 01/2010.
  • Genentech: FVF4166g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Central Retinal Vein Occlusion, 02/2008 – 01/2010.
  • Genentech: FVF4168g, Sub-Investigator, Intravitreal Injection of Ranibizumab for Diabetic Macular Edema, 08/2007 – 12/2012.
  • Genentech: FVF4295, Sub-Investigator, Evaluation of Ranibizumab on Ease of Procedure and Complications in PDR Requiring Vitrectomy, 09/2007 – 10/2010.
  • Genentech: FVF3426g, Sub-Investigator, Intravitreal Injections of Ranibizumab for Branch Retinal Vein Occlusion and Central Retinal Vein Occlusion for Subjects who have Completed a Genentech Sponsored Ranibizumab Study, 02/2009 – 10/2010.
  • Genentech: FVF4579g, Sub-Investigator, Intravitreal Injection of Either 0.5mg or 2.0mg Ranibizumab Administered Monthly or on an as Needed Basis for Subjects with Subfoveal Neovascular Age-Related Macular Degeneration, 06/2009 – 09/2012.
  • Genentech: FVF4967g, Sub-Investigator, Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion, 03/2011 - 01/2013.
  • Genentech: GX29176, Sub-Investigator, Study to Assess the efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration. 11/2014 - present.
  • Genentech: GX30191, Sub-Investigator, Open Label Extension to Evaluate the Long-term Safety and Tolerability of Lampalizumab in Patients with Geographic Atrophy Secondary to NNVAMD who have Completed a Roche-Sponsored Study, 10/2016 - present.
  • Genentech: GR40548, Sub-Investigator, Phase III, Active-Comparator Study of the Efficacy, Safety and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration, 11/2019 - present.
  • Genentech: GR40349, Sub-Investigator, Phase III, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema., 11/2018 - present.
  • Genentech: GR40306, Sub-Investigator, Phase III, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Neovascular Age-Related Macular Degeneration, 03/2019 - present.
  • Genentech: GR40549, Sub-Investigator, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of the Port Deliver System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration, 10/2020 - present.
  • Genentech: GR40550, Sub-Investigator, Phase III, Study of the Efficacy, Safety and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema, 09/2019 - present.
  • Genentech: GR41675, Sub-Investigator, Phase III, Study of the Efficacy, Safety and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy, 09/2020 - present.
  • Eli Lily: B7A-MC-MBCM, Sub-Investigator, Ruboxistaurin Mesylate for Patients with Diabetic Retinopathy. 01/2003– 04/2006.
  • Eli Lily: B7A-MC-MBDV, Sub-Investigator, Open-Label treatment for Patients Completing Study B7A-MC-MBCM, 02/2006-11/2008.
  • Kodiak: KSI-CL-102, Sub-Investigator, Phase III, Active Comparator-Controlled Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular Age-Related Macular Degeneration. 09/2019 - present.
  • MyLan: MYL-1701P-3001, Sub- Investigator, Active-Controlled, Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Aflibercept in Subjects with Diabetic Macular Edema, 08/2018 - present.
  • National Eye Institute SCORE2: Sub-Investigator, Study of Comparative Treatments for Retinal Vein Occlusion, 10/2014 - 5/2016.
  • NGM Bio: NGM621-GA-201, Sub-Investigator, Phase II, Double-Masked, Sham-Controlled Study of the Efficacy and Safety of Intravitreal Injections of NGM621 in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration, 09/2020 - present.
  • Novartis: Principal Investigator, Insight CNV Registry, 11/2005 – 08/2006.
  • Novartis: CRTH258B2301, Sub-Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment Due to Diabetic Macular Edema, 09/2018 - present.
  • Novartis: CRTH258AUS04, Sub-Investigator, Phase III Study to Assess Safety and Efficacy of Brolucizumab 6mg q4weeks Compared to Aflibercept 2mg q4weeks in Patients with Neovascular Age-Related Macular Degeneration with Persistent Retinal Fluid, 12/2018 - present.
  • Novartis: CRTH258C2301, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion, 07/2019 - present.
  • Novartis: CRTH258C2302, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion, 07/2018 - present.
  • Novartis: CRTH258B2305, Sub-Investigator, Study to Assess Safety and Efficacy of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment Due to Diabetic Macular Edema, 10/2019 - present.
  • Ophthotech: OPH3000, Principal Investigator, Intravitreal Injection of Volociximab in Combination with Ranibizumab for Neovascular Age-Related Macular Degeneration, 10/2008 – 12/2009.
  • Ophthotech: OPH1001, Principal Investigator, Intravitreal Injection of E10030 (Anti-PDGF-B Pegylated Aptamer) in Combination with Ranibizumab for Neovascular Age-Related Macular Degeneration, 05/2010 – 11/2001.
  • Ophthotech: OPH1003, Principal Investigator, Intravitreal Injection of Fovista (Anti-PDGF-B Pegylated Aptamer) in Combination with Lucentis vs. Lucentis Monotherapy for the Treatment of Neovascular Age-Related Macular Degeneration, 09/2013 - 01/2017.
  • Ophthotech: OPH1004, Principal Investigator, Intravitreal Injection of Fovista (Anti-PDGF Pegylated Aptamer) in Combination with Eylea or Avastin Compared vs. Eylea or Avastin Monotherapy for the Treatment of Neovascular Age-Related Macular Degeneration, 07/2015 - 09/2017.
  • Pan Optica: PAN-01-101, Principal Investigator, Study to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Neovascular Age-Related Macular Degeneration, 01/2014 - 03/2016.
  • Regeneron: R2176-3-AMD-1417, Sub-Investigator, multiple Dose, Regimen Ranging Study of the Efficacy and Safety of Intravitreal REGN2176-3 in Patients with Neovascular Age-Related Macular Degeneration, 06/2015 - 04-2017.
  • Regeneron: R910-3-DME-1518, Sub-Investigator, Intravitreal REGN910-3 for Patients with Diabetic Macular Edema, 05/2016 - 10/2017.
  • Principal Investigator, Submacular Surgery Trials. 1998 - 1999
  • Principal Investigator, An Open Label Study of the Safety and Efficacy of Intravitreal ISIS 2922 in Acquired Immune Deficiency Syndrome (AIDS) Patients with Cytomegalovirus Retinitis. (Protocol ISIS 2922-CS7) 1997
  • Clinical Investigator, ASPEN Diabetic Retinopathy Substudy. 1997
  • Clinical Investigator, Age-Related Eye Disease Study (AREDS). (NIH Grant #NO1-#EY02124) 1995
  • Co-Investigator, Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity. 1995
  • Clinical Investigator, Silicone Oil Study. 1995
  • Clinical Investigator, Perfluorone Study. 1995